Novel Gd nanoparticles enhance vascular contrast for high-resolution magnetic resonance imaging

PLoS ONE

Volumn 5, Issue 9, 2010, Pages 1-7

  Bui, Tot ^a   Stevenson, Jeff ^b   Hoekman, John ^a   Zhang, Shanrong ^b   Maravilla, Kenneth ^b   Ho, Rodney J Y ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GADOLINIUM; NANOPARTICLE; PENTETIC ACID; CONTRAST MEDIUM; DIAGNOSTIC AGENT;

ANIMAL EXPERIMENT; ARTICLE; BIOCOMPATIBILITY; CONTROLLED STUDY; DOSE RESPONSE; DRUG CLEARANCE; DRUG DESIGN; DRUG SAFETY; GEL PERMEATION CHROMATOGRAPHY; IMAGE ENHANCEMENT; IMAGE PROCESSING; IMAGE QUALITY; LOW DRUG DOSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PROCESS OPTIMIZATION; RAT; RECOMMENDED DRUG DOSE; SENSITIVITY AND SPECIFICITY; SIGNAL NOISE RATIO; ANIMAL; CHEMISTRY; INSTRUMENTATION; MAGNETIC RESONANCE ANGIOGRAPHY; METHODOLOGY;

RATTUS;

ANIMALS; CONTRAST MEDIA; GADOLINIUM; MAGNETIC RESONANCE ANGIOGRAPHY; NANOPARTICLES; RATS;

EID: 77958563232     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0013082     Document Type: Article

References (13)

1. Rofsky NM, Sherry AD, Lenkinski RE (2008) Nephrogenic systemic fibrosis: a chemical perspective. Radiology 247: 608-612.
2. FDA (2007) Information for Healthcare Professionals Gadolinium-Based Contrast Agents for Magnetic Resonance Imaging (marketed as Magnevist, MultiHance, Omniscan, OptiMARK, ProHance). FDA ALERT: US FDA. This updated Alert highlights FDA's request for addition of a boxed warning and new warnings about risk of nephrogenic systemic fibrosis (NSF) to the full prescribing information for all gadoliniumbased contrast agents (GBCAs) (Magnevist, MultiHance, Omniscan, OptiMARK, ProHance).
3. Huang SK, Lee KD, Hong K, Friend DS, Papahadjopoulos D (1992) Microscopic localization of sterically stabilized liposomes in colon carcinomabearing mice. Cancer Res 52: 5135-5143.
4. Hak S, Sanders HM, Agrawal P, Langereis S, Grull H, et al. (2008) A high relaxivity Gd(III)DOTA-DSPE-based liposomal contrast agent for magnetic resonance imaging. Eur J Pharm Biopharm.
5. Meaney JF, Goyen M (2007) Recent advances in contrast-enhanced magnetic resonance angiography. Eur Radiol 17 Suppl 2: B2-B6.
6. Woods M, Zhang S, Sherry AD (2004) Toward the design of MR agents for imaging b-cell function. Current Medicinal Chemistry: Immunology, Endocrine & Metabolic Agents 4: 349-369.
7. Solomon I, Bloembergen N (1956) Nuclear Magnetic Interactions in the HF Molecule. The Journal of Chemical Physics 25: 261-266.
8. Sitharaman B, Kissell KR, Hartman KB, Tran LA, Baikalov A, et al. (2005) Superparamagnetic gadonanotubes are high-performance MRI contrast agents. Chem Commun (Camb). pp 3915-3917.
9. Neubauer AM, Sim H, Winter PM, Caruthers SD, Williams TA, et al. (2008) Nanoparticle pharmacokinetic profiling in vivo using magnetic resonance imaging. Magn Reson Med 60: 1353-1361.
10. Trubetskoy VS, Cannillo JA, Milshtein A, Wolf GL, Torchilin VP (1995) Controlled delivery of Gd-containing liposomes to lymph nodes: surface modification may enhance MRI contrast properties. Magn Reson Imaging 13: 31-37.
11. Peters T, Jr., Peters JC (1972) The Biosynthesis of Rat Serum Albumin. VI. INTRACELLULAR TRANSPORT OF ALBUMIN AND RATES OF ALBUMIN AND LIVER PROTEIN SYNTHESIS IN VIVO UNDER VARIOUS PHYSIOLOGICAL CONDITIONS. J Biol Chem 247: 3858-3863.
12. Ballmer PE (2001) Causes and mechanisms of hypoalbuminaemia. Clinical Nutrition 20: 271-273.
13. Lauffer RB, Parmelee DJ, Dunham SU, Ouellet HS, Dolan RP, et al. (1998) MS-325: albumin-targeted contrast agent for MR angiography. Radiology 207: 529-538.